Parkinson's Disease Levodopa-induced Dyskinesia Market to Exhibit Growth at a CAGR of X% by 2032, estimates DelveInsight

DelveInsight's 'Parkinson's Disease Levodopa-Induced Dyskinesia Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of PD-LID in the United States, Japan, EU4 (Germany, Spain, Italy, France) and the UK.

Key Takeaways from the Parkinson's Disease Levodopa-induced Dyskinesia Market Report
• The increase in Parkinson's Disease Levodopa-induced Dyskinesia Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Parkinson's Disease Levodopa-induced Dyskinesia market is anticipated to witness growth at a considerable CAGR.
• The leading Parkinson's Disease Levodopa-induced Dyskinesia Companies working in the market include PharmaTher Inc., Neurolixis SAS, Gala laboratories, Bukwang Pharmaceutical, Contera Pharma, Vistagen, Ipsen Pharma, Newron Pharmaceuticals, Zambon Pharmaceuticals, Celon Pharma SA, and others.
• Promising Parkinson's Disease Levodopa-induced Dyskinesia Therapies in the various stages of development include DSP-9632P 27.5 mg, ADS-5102, AFQ056, JM-010, and others.
• April 2024:- Neurolixis SAS- A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in Levodopa-induced Dyskinesia in Parkinson's Disease. This is a double-blind, randomized, placebo-controlled Phase 2a study evaluating the safety, tolerability, and preliminary efficacy of up to 2 mg/day (1 mg BID) of NLX-112 versus placebo in patients with moderate to severe L-DOPA induced dyskinesia (LID) in Parkinson's disease (PD). NLX-112 will be up-titrated to either 2 mg/day or to the highest well-tolerated dose less than 2 mg/day over 4 weeks, maintained at the well-tolerated dose for an additional 2 weeks, and then down-titrated over 2 weeks.
• March 2024:- Integrative Research Laboratories AB- A Randomized, Double-blind, Placebo-controlled Phase IIB Study Evaluating the Efficacy of Mesdopetam on Daily ON-time Without Troublesome Dyskinesia in Patients With Parkinson's Disease. This is a Phase 2b study investigating the efficacy and safety of mesdopetam as adjunct therapy on daily ON-time without troublesome dyskinesia in patients with Parkinson disease. Mesdopetam is taken for 84 days.
• February 2024:- Celon Pharma SA- Phase II, Double Blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A Inhibitor) in Patients With Parkinson's Disease Suffering From Levodopa Induced Dyskinesia. The aim of the study is to determine potential anti-dyskinetic properties of CPL500036 (PDE10A inhibitor) in Parkinson disease patients suffering from levodopa Induced dyskinesia. The study is to determine the efficacy and dose response of two CPL500036 doses, compared with placebo.

Discover which therapies are expected to grab the Parkinson's Disease Levodopa-induced Dyskinesia Market Share @ Parkinson's Disease Levodopa-induced Dyskinesia Market Outlook- https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Parkinson's Disease Levodopa-induced Dyskinesia Overview
Parkinson's Disease Levodopa-induced Dyskinesia (PD-LID) is a condition that occurs as a side effect of long-term treatment with levodopa, which is a common medication used to manage the symptoms of Parkinson's disease. Dyskinesia refers to involuntary, uncontrollable movements that can affect various parts of the body, such as the arms, legs, face, or trunk. In PD-LID, these dyskinetic movements typically develop as a result of prolonged use of levodopa therapy. While levodopa is effective in alleviating the motor symptoms of Parkinson's disease, such as tremors, stiffness, and slowness of movement, over time it can lead to abnormal and involuntary movements.

Parkinson's Disease Levodopa-induced Dyskinesia Epidemiology Insights
The epidemiology section of Parkinson's Disease Levodopa-induced Dyskinesia offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Parkinson's Disease Levodopa-induced Dyskinesia Epidemiology trends @ Parkinson's Disease Levodopa-induced Dyskinesia Epidemiological Insights- https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Parkinson's Disease Levodopa-induced Dyskinesia Drugs Market
The Parkinson's Disease Levodopa-induced Dyskinesia Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Parkinson's Disease Levodopa-induced Dyskinesia signaling in Parkinson's Disease Levodopa-induced Dyskinesia are likely to uncover new therapeutic targets and further expand treatment options for patients.

Parkinson's Disease Levodopa-induced Dyskinesia Treatment Market Landscape
The Parkinson's Disease Levodopa-induced Dyskinesia treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Parkinson's Disease Levodopa-induced Dyskinesia has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To know more about Parkinson's Disease Levodopa-induced Dyskinesia treatment guidelines, visit @ Parkinson's Disease Levodopa-induced Dyskinesia Treatment Market Landscape- https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Parkinson's Disease Levodopa-induced Dyskinesia Market Outlook
The report's outlook on the Parkinson's Disease Levodopa-induced Dyskinesia market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Parkinson's Disease Levodopa-induced Dyskinesia therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Parkinson's Disease Levodopa-induced Dyskinesia drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Parkinson's Disease Levodopa-induced Dyskinesia market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

Parkinson's Disease Levodopa-induced Dyskinesia Drugs Uptake
The drug chapter of the Parkinson's Disease Levodopa-induced Dyskinesia report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Parkinson's Disease Levodopa-induced Dyskinesia.

Major Parkinson's Disease Levodopa-induced Dyskinesia Companies
Several Parkinson's Disease Levodopa-induced Dyskinesia Companies working in the market include PharmaTher Inc., Neurolixis SAS, Gala laboratories, Bukwang Pharmaceutical, Contera Pharma, Vistagen, Ipsen Pharma, Newron Pharmaceuticals, Zambon Pharmaceuticals, Celon Pharma SA, and others.

Learn more about the FDA-approved drugs for Parkinson's Disease Levodopa-induced Dyskinesia @ Drugs for Parkinson's Disease Levodopa-induced Dyskinesia Treatment- https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Parkinson's Disease Levodopa-induced Dyskinesia Market Research Report
• Coverage- 7MM
• Study Period- 2019-2032
• Parkinson's Disease Levodopa-induced Dyskinesia Companies- PharmaTher Inc., Neurolixis SAS, Gala laboratories, Bukwang Pharmaceutical, Contera Pharma, Vistagen, Ipsen Pharma, Newron Pharmaceuticals, Zambon Pharmaceuticals, Celon Pharma SA, and others.
• Parkinson's Disease Levodopa-induced Dyskinesia Pipeline Therapies- DSP-9632P 27.5 mg, ADS-5102, AFQ056, JM-010, and others.
• Parkinson's Disease Levodopa-induced Dyskinesia Market Dynamics: Parkinson's Disease Levodopa-induced Dyskinesia Market Drivers and Barriers
• Parkinson's Disease Levodopa-induced Dyskinesia Market Access and Reimbursement, Unmet Needs, KOL's Views, and Analyst's Views

Discover more about Parkinson's Disease Levodopa-induced Dyskinesia Drugs in development @ Parkinson's Disease Levodopa-induced Dyskinesia Clinical Trials Assessment- https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Parkinson's disease Levodopa-induced dyskinesia (PD-LID), Market Overview at a Glance
4. Executive Summary of Parkinson's disease Levodopa-induced Dyskinesia (PD-LID)
5. Key Events
6. Disease Background and Overview
8. Patient Journey
9. Marketed Product
10. Emerging therapies
11. PD-LID: Seven Major Market Analysis
12. KOL Views
13. SWOT Analysis
14. Unmet Needs
15. Market Access and Reimbursement
16. Acronyms and Abbreviations
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.